# PathAI

> PathAI develops AI-powered tissue-analysis tools and cloud-based digital pathology software for biopharma companies, pathology laboratories and health systems. Its AISight platform supports slide and case management, while its research and clinical-trial services turn tissue images into measurements for biomarker discovery and drug development.

- **Founded:** 2016
- **Headquarters:** Boston, United States
- **Founders:** Andrew Beck (Co-founder and CEO), Aditya Khosla (Co-founder and CTO (identified in Beck’s May 2026 essay))
- **Products:** AISight, AISight Dx, PathExplore, AIM-MASH AI Assist, AIM-HI UC and IBDExplore
- **Notable:** Initial AISight Dx(Novo) FDA clearance in 2022; evolved AISight Dx platform clearance in June 2025 with a Predetermined Change Control Plan., FDA qualification of AIM-NASH/AIM-MASH AI Assist for defined MASH clinical-trial use in December 2025., PathAI reports a contributor network of more than 450 pathologists and more than 32.5 million annotations.

## Products & services

- **AISight** — Cloud-native image and case management platform with laboratory information system integration and PathAI and third-party AI applications; research-use platform in the US.
- **AISight Dx** — Digital pathology image management system FDA-cleared for primary diagnosis with specified compatible scanners; evolved platform cleared in June 2025 following an initial 2022 clearance.
- **PathExplore** — Research-use spatial tissue analysis of the tumor microenvironment from histopathology images.
- **AIM-MASH AI Assist** — AI-assisted liver-biopsy scoring tool qualified by EMA and FDA in 2025 for defined use in MASH clinical trials; formerly AIM-NASH.
- **AIM-HI UC and IBDExplore** — AI-assisted ulcerative colitis scoring and spatial analysis of the inflammatory microenvironment, expanded on the clinical-trials platform in February 2026.
- **BioPharma Services** — Translational research, custom algorithm development, clinical-trial pathology and lab services, companion diagnostic development and quantitative real-world data licensing.
- **PathAssist Derm** — AI-assisted skin-specimen workflow tool; received FDA Breakthrough Device Designation in March 2026, which is not marketing clearance.

## Achievements

- Initial AISight Dx(Novo) FDA clearance in 2022; evolved AISight Dx platform clearance in June 2025 with a Predetermined Change Control Plan.
- FDA qualification of AIM-NASH/AIM-MASH AI Assist for defined MASH clinical-trial use in December 2025.
- PathAI reports a contributor network of more than 450 pathologists and more than 32.5 million annotations.
- PathAI reports 100+ institutions using AISight and more than 100 million digital slides managed.

## Latest updates

- **2026-07** — AISight Dx v2.21 released July 28 with customizable dashboard widgets, bulk annotation management, editable measurements, collaboration changes and archiving support.
- **2026-05** — Roche announced a definitive merger agreement on May 7: $750 million upfront plus up to $300 million in milestone payments, subject to closing conditions. The announcement expected closing in the second half of 2026; no completion is asserted here.
- **2026-04** — MedStar Health partnership announced April 7.
- **2026-03** — PathAssist Derm received FDA Breakthrough Device Designation.
- **2026-02** — Labcorp announced nationwide AISight Dx deployment collaboration; PathAI expanded AIM-HI UC and IBDExplore on its clinical-trials platform.

## Links

- Website: https://www.pathai.com/
- LinkedIn: https://www.linkedin.com/company/pathai
- Twitter/X: https://twitter.com/path_ai
- GitHub: https://github.com/Path-AI
- YouTube: https://www.youtube.com/@Path_AI
- Facebook: https://www.facebook.com/PathAIInc

---

Profile page: https://yespress.io/pathai
Published by YesPress — https://yespress.io
Last updated: 2026-10-02